Global Peptide Therapeutics Market 2019-2023
SKU ID : TNV-14770498 | Publishing Date : 24-Dec-2018 | No. of pages : 118
Detailed TOC of Global Peptide Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY ROA
• Market segmentation by RoA
• Comparison by RoA
• Parenteral - Market size and forecast 2018-2023
• Oral - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by RoA
PART 07: MARKET SEGMENTATION BY INDICATION
PART 08: MARKET SEGMENTATION BY TECHNOLOGY
PART 09: CUSTOMER LANDSCAPE
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Eli Lilly
• Novo Nordisk
• Sanofi
• Takeda Pharmaceutical
• Teva Pharmaceutical
PART 15: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: RoA - Market share 2018-2023 (%)
Exhibit 19: Comparison by RoA
Exhibit 20: Parenteral - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Parenteral - Year-over-year growth 2019-2023 (%)
Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Others - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by RoA
Exhibit 27: Market share by 2018-2023 (%)
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Eli Lilly - Vendor overview
Exhibit 47: Eli Lilly - Business segments
Exhibit 48: Eli Lilly - Organizational developments
Exhibit 49: Eli Lilly - Geographic focus
Exhibit 50: Eli Lilly - Segment focus
Exhibit 51: Eli Lilly - Key offerings
Exhibit 52: Eli Lilly - Key customers
Exhibit 53: Novo Nordisk - Vendor overview
Exhibit 54: Novo Nordisk - Business segments
Exhibit 55: Novo Nordisk - Organizational developments
Exhibit 56: Novo Nordisk - Geographic focus
Exhibit 57: Novo Nordisk - Segment focus
Exhibit 58: Novo Nordisk - Key offerings
Exhibit 59: Novo Nordisk - Key customers
Exhibit 60: Sanofi - Vendor overview
Exhibit 61: Sanofi - Business segments
Exhibit 62: Sanofi - Organizational developments
Exhibit 63: Sanofi - Geographic focus
Exhibit 64: Sanofi - Segment focus
Exhibit 65: Sanofi - Key offerings
Exhibit 66: Sanofi - Key customers
Exhibit 67: Takeda Pharmaceutical - Vendor overview
Exhibit 68: Takeda Pharmaceutical - Business segments
Exhibit 69: Takeda Pharmaceutical - Organizational developments
Exhibit 70: Takeda Pharmaceutical - Geographic focus
Exhibit 71: Takeda Pharmaceutical - Key offerings
Exhibit 72: Takeda Pharmaceutical - Key customers
Exhibit 73: Teva Pharmaceutical - Vendor overview
Exhibit 74: Teva Pharmaceutical - Business segments
Exhibit 75: Teva Pharmaceutical - Organizational developments
Exhibit 76: Teva Pharmaceutical - Geographic focus
Exhibit 77: Teva Pharmaceutical - Segment focus
Exhibit 78: Teva Pharmaceutical - Key offerings
Exhibit 79: Teva Pharmaceutical - Key customers
Exhibit 80: Validation techniques employed for market sizing
Exhibit 81: List of abbreviations
Keyplayers in Global Peptide Therapeutics Market 2019-2023
Eli LillyNovo Nordisk
Sanofi
Takeda Pharmaceutical
Teva Pharmaceutical